Botulinum toxin A (Botox® cosmetic): A review of its use in the treatment of glabellar frown lines

被引:42
作者
Frampton, JE [1 ]
Easthope, SE [1 ]
机构
[1] Adis Int Inc, Yardley, PA 19047 USA
关键词
D O I
10.2165/00128071-200304100-00005
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Botox(R) Cosmetic (Botox(R)) is a formulation of the neuromuscular blocking agent botulinum toxin type A (BTX-A). When injected into hyperactive corrugator superciliaris and/or procerus muscles of the face that predominantly control frowning, Botox(R) produces a transient (3- to 6-month), dose-dependent localized muscle weakness, resulting in a temporary improvement in glabellar frown lines ('brow furrows'). After a decade of successful 'off-label' use, the efficacy and tolerability of Botox(R) (total dose 20 biological units) in the treatment of glabellar frown lines have been demonstrated in two identical, large, multicenter, randomized, double-blind, placebo-controlled pivotal trials in a total of 537 subjects, mostly women, with moderate or severe glabellar lines during facial animation. Based both on subjects' and physicians' assessments, the improvement in glabellar lines with Botox(R) was superior to that with placebo at each visit during the 120-day post-injection follow-up period, beginning on day 7 post-injection. The peak effect was seen on day 30 post-injection when 80% of subjects in the two studies combined had the severity of their lines at maximum frown reduced to mild or none, as assessed by their physician, and 89% had at least a moderate (greater than or equal to50%) improvement in the appearance of their glabellar lines, as rated by themselves. In a noncomparative extension of these trials, there was a tendancy for a higher proportion of subjects to respond to Botox(R) injections after a second and third treatment session. Botox(R) injections for glabellar lines are well tolerated. Headache, the most common adverse event, occurred with a similar frequency to placebo in the two pivotal studies (13% vs 18%). Temporary blepharoptosis occurred in 3.2% of Botox(R) recipients; however, the incidence of this adverse event tended to decrease with repeated treatment sessions. In summary, Botox(R) injections offer a convenient, effective, and well tolerated treatment for improving glabellar frown lines. Repeated injections are necessary to maintain a long-term effect; however, this technique clearly represents an attractive option for individuals who wish to avoid a more major procedure.
引用
收藏
页码:709 / 725
页数:17
相关论文
共 61 条
[1]   Botulinum toxin A for the treatment of facial hyperkinetic wrinkle lines in Koreans [J].
Ahn, KY ;
Park, MY ;
Park, DH ;
Han, DG .
PLASTIC AND RECONSTRUCTIVE SURGERY, 2000, 105 (02) :778-784
[2]   Botulinum A exotoxin for hyperfunctional facial lines - Where not to inject [J].
Alam, M ;
Dover, JS ;
Klein, AW ;
Arndt, KA .
ARCHIVES OF DERMATOLOGY, 2002, 138 (09) :1180-1185
[3]  
*ALL INC, 2002, BOT COSM BOT TOX TYP
[4]  
*AM AC DERM, 2003, BOT REJ NEW TECHN HE
[5]  
*AM AC OPHTH, BOT TOX TYP SEV GLAB
[6]   Botulinum toxin A in the therapy of mimic facial lines [J].
Becker-Wegerich, P ;
Rauch, L ;
Ruzicka, T .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (07) :619-630
[7]   The cosmetic uses of Botulinum toxin type A [J].
Benedetto, AV .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1999, 38 (09) :641-655
[8]  
Blitzer A, 1997, ARCH OTOLARYNGOL, V123, P389
[9]  
BLITZER A, 1993, ARCH OTOLARYNGOL, V119, P1018
[10]  
Blitzer A, 2001, Facial Plast Surg Clin North Am, V9, P395